Grateful for the opportunity to give back to our community by helping to stock the Watertown Community Fridge. #givingback

We’re excited to announce that Jared Haney has joined our team as the Director of Finance & Accounting. With a wealth of experience in financial reporting, Jared will assist us with building & maintaining budgets that guide our business strategy & more. #newhire #biotech

CEO Catherine Sabatos-Peyton will present at the following upcoming biotech events: Boost by BioBreak (virtual) – Dec. 18, 2023 Longwood Healthcare Leaders San Francisco CEO (SF) – Jan. 7, 2024 Fierce JPM Week (SF) – Jan. 10, 2024 Fierce Life Sciences Events bit.ly/3ToFKdC #FierceJPM #biotech

2023 was quite a year of exciting milestones — from launching with our Series A and growing our team to presenting at #SITC2023 and other key conferences. Our incredible and dedicated team is at the heart of this progress, and we’re thrilled about what’s in store for 2024.

Welcome to Warda Ahmed, a Northeastern University University student who will spend 6 months at Larkspur as a research assistant co-op. Warda will support cell-based assay development with other members of the biology research team. #biotech #coop #intern

Cancer txs have come a long way but many patients still respond poorly or not at all. At Larkspur, we’re developing a new wave in cancer therapy that stops immune evasion where it starts: in the tumor. Learn how we're closing the care gap: bit.ly/3HGxDC6 #WorldCancerDay

The rise of colorectal cancer (CRC) among young adults is alarming, and new treatment options are needed. At Larkspur, we’re pioneering a new wave of cancer treatment, and our lead programs initially target CRC. #ColorectalCancerAwarenessMonth #Cancer

Attending the AACR Annual Meeting? We’re presenting new research on LRK-A, our 1st-in-class PIP4K2C protein degrader. The preclinical data demonstrate that LRK-A drives anti-tumor activity in vivo in colorectal cancer models. Learn more: bit.ly/3VFTqCf #Cancer #AACR24

Tomorrow at #AACR24: Don’t miss our presentation on our 1st-in-class, lead investigational therapy targeting the lipid kinase PIP4K2C. Data show the potential of targeted PIP4K2C degradation to treat colorectal cancer. More: bit.ly/3VFTqCf #Cancer

CEO Catherine Sabatos-Peyton recently shared her insights on advanced AI and biophysical modeling with Outsourcing-Pharma for its Vox Pop Pharma series. More: bit.ly/3xHUfk7 #AI #drugdiscovery

This is the closest we ever got to improving survival in a randomized Phase 3 trial for higher risk #MDSsm. Can’t describe the disappointment when p-value came at 0.08, but I look forward to presenting data in #EHA2024, & I still believe in TIM3 targeting library.ehaweb.org/eha/2024/eha20…

Thrilled to be in our new lab space in Cambridge and one of the first tenants of One Canal by Breakthrough Properties. Larkspur occupies 12,500 square feet—50% more space than our previous location. Ck out the Boston Business Journal article on One Canal: bit.ly/3QSctWD. #Biotech #Research

Larkspur’s Catherine Sabatos-Peyton & Emily Corse are in Chicago for #ASCO24. They’re looking forward to connecting with peers, like our SAB member Toni Ribas, and discussing new advances in cancer treatment. #ASCO2024

We’re excited to share that the ACS Organic Division has awarded Larkspur scientist Morgan O’Shea a 2024 Technical Achievement in Organic Chemistry (TAOC) Award. Congrats, Morgan! #MedChem #biotech #ACSFall2024

MonkeyMindEscape.com

#SITC2024: We’re thrilled to share new data on the therapeutic potential of tumor fitness targets PIP4K2C & Pin1. Our PIP4K2C preclinical study shows that our 1st-in-class protein degrader can specifically target PIP4K2C & reduce tumor growth in CRC patient samples. Society for Immunotherapy of Cancer

Don’t miss our @sitccancer presentations on key tumor fitness targets: * new data on our 1st-in-class PIP4K2C protein degrader * Pin1 degradation as a promising treatment * how our ML-enabled immune evasion signature models can predict responses to cancer therapy #SITC2024

Larkspur CEO, Catherine Sabatos-Peyton, will share her perspective on the impact of the #InflationReductionAct on innovation in drug development at a @Lumanity webinar tomorrow. Register at bit.ly/3UK1UH6 #biotech #drugdiscovery

Earlier this fall, our team volunteered to pack curriculum supplies for the Science Club for Girls. We’re grateful for opportunities like this to help more girls and gender-expansive youth discover the wonders of #STEM. #culture #biotech

Our CEO, Catherine Sabatos-Peyton, will join a panel of experts discussing “Accessing Technology to Advance the Pipeline” at the Longwood Healthcare Leaders San Francisco CEO forum on Sunday, Jan. 12. More here: bit.ly/426Q3HU